EUVIMEDEUVIMED entdecken
Crossref

Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis

Yan-fang Chen, Ze-kai Fan, Yin-peng Wang, Peng Liu, Yi-xuan Cong, Yuan Wang, Ting Zhao, Tong-cheng Xu, Andrew J Sinclair, Duo Li, Xiao-fei Guo

Food Science and Human Wellness · 2025-11

DOI: 10.26599/fshw.2025.9250806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Food Science and Human Wellness, 2025-11. Verfasst von Yan-fang Chen und 10 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated fatty liver disease (MAFLD), characterized as hepatic triglyceride accumulation, affects a quarter of the adult population worldwide, but limited therapeutic approaches are available in the treatment of MAFLD. It is widely believed that marine n-3 polyunsaturated fatty acids (PUFA) intervention could ameliorate MAFLD, however, the underlying mechanism remains elusive. Herein, in a case-control study, we identified serum C16:0-ceramide as a biomarker indicating MAFLD patients, which was negatively associated with n-3 PUFA levels in red blood cell phospholipids. The causality was confirmed by a randomized controlled trial (RCT), highlighting that supplemental n-3 PUFA had notable action in lowering serum C16:0-ceramide concentrations. The RCT indicated that serum adiponectin levels were negatively associated with serum C16:0-ceramide levels. An MAFLD model was established in mice fed a high-fat, high-cholesterol diet, and administration of n-3 PUFA increased adiponectin secretion and decreased hepatic C16:0-ceramide concentrations associated with reduced hepatic steatosis. In these mice, adiponectin administration contributed to decreased hepatic C16:0-ceramide concentrations and alleviated hepatic triglyceride accumulation through reduced de novo fatty acid synthesis and increased fatty acid β-oxidation. Furthermore, administration of C16:0-ceramide reversed the beneficial effects of n-3 PUFA in high-fat diet-induced MAFLD. This work reveals a novel mechanism, namely adiponectin-C16:0-ceramide axis, through which n-3 PUFA play a notable role in ameliorating MAFLD.

Zitieren

APA

Chen, Y., Fan, Z., Wang, Y., Liu, P., Cong, Y., Wang, Y., Zhao, T., Xu, T., Sinclair, A. J., Li, D., & Guo, X. (2025). Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis. Food Science and Human Wellness. https://doi.org/10.26599/fshw.2025.9250806

Vancouver

Chen Y, Fan Z, Wang Y, Liu P, Cong Y, Wang Y, et al. Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis. Food Science and Human Wellness. 2025. doi:10.26599/fshw.2025.9250806

BibTeX
@article{Chen2025,
  author = {Chen, Yan-fang and Fan, Ze-kai and Wang, Yin-peng and Liu, Peng and Cong, Yi-xuan and Wang, Yuan and Zhao, Ting and Xu, Tong-cheng and Sinclair, Andrew J and Li, Duo and Guo, Xiao-fei},
  title = {Marine n-3 Polyunsaturated Fatty Acids Alleviate Metabolic Dysfunction-Associated Fatty Liver Disease Through Adiponectin-Ceramide Axis},
  journal = {Food Science and Human Wellness},
  year = {2025},
  doi = {10.26599/fshw.2025.9250806}
}
Kostenlos starten →